高效液相色谱法同时测定三七中5种核苷和碱基的含量

摘要/Abstract

摘要：

目的测定三七不同部位中5种核苷类成分胞苷、尿苷、鸟苷、腺苷和尿嘧啶含量。方法采用Zorbax SB-Aq色谱柱；以8 mmol·L^–1醋酸铵水溶液 (A) 和甲醇 (B) 为流动相梯度洗脱，在 25 ºC条件下流速为1 mL·min^–1；检测波长为260 nm。结果胞苷、尿苷、鸟苷、腺苷和尿嘧啶线性范围分别为1.79 – 57.40 μg·mL^–1 (r² = 1.0000)，3.30 – 105.60 μg·mL^–1 (r² =1.0000)，3.09 – 98.80 μg·mL^–1 (r² = 0.9999)，2.77 – 88.60 μg·mL^–1 (r² = 1.0000)和0.38 – 12.30 μg·mL^–1 (r² = 1.0000)；加样回收率分别为93.9%，96.5%，92.7%，93.2%和98.8%。三七不同部位中5种核苷类成分的含量差异显著。结论本文首次报道了三七中核苷类成分的含量，其对完善三七药材的质量控制具有一定的指导意义。

关键词: 三七, 三七, 三七, 核苷, 核苷, 核苷, 碱基, 碱基, 碱基, 高效液相色谱法, 高效液相色谱法, 高效液相色谱法

Abstract: Aim To quantitatively determine five nucleosides and nucleobases, including cytidine, uridine, guanosine, adenosine and uracil in different parts of Panax notoginseng. Methods Separation was performed on a Zorbax SB-Aq column using a gradient elution with mobile phase of 8 mmol·L^–1 ammonium acetate aqueous solution (A) and methanol (B). The assay was carried out at a flow rate of 1 mL·min^–1 at 25 ºC with the diode-array detection at 260 nm. Results Cytidine, uridine, guanosine, adenosine and uracil had good linearity in the ranges of 1.79 – 57.40 μg·mL^–1 (r² = 1.0000), 3.30 – 105.60 μg·mL^–1 (r² = 1.0000), 3.09 – 98.80 μg·mL^–1 (r² = 0.9999), 2.77 – 88.60 μg·mL^–1 (r² = 1.0000) and 0.38 – 12.30 μg·mL^–1 (r² = 1.0000) with average recoveries of 93.9%, 96.5%, 92.7%, 93.2% and 98.8%, respectively. The content of cytidine, uridine, guanosine, adenosine and uracil in different parts of P. notoginseng were significantly different. Conclusion This is the first report on quantitative determination of nucleosides and nucleobases in P. notoginseng.

Key words: Panax notoginseng, Panax notoginseng, Nucleoside, Nucleoside, Nucleobase, Nucleobase, High-performance liquid chromatography HPLC, High-performance liquid chromatography HPLC

中图分类号:

R917

Supporting: ^*Corresponding author. Tel.: 853-3974692; fax: 853-28841358

王静, 王一涛, 李绍平^*. 高效液相色谱法同时测定三七中5种核苷和碱基的含量[J]. .

Jing Wang, Yi-Tao Wang, Shao-Ping Li^*. Simultaneous determination of five nucleosides and nucleobases in Panax notoginseng using high-performance liquid chromatography[J]. .

参考文献

[1] Dong TT, Zhao KJ, Huang WZ, et al. Orthogonal array design in optimizing the extraction efficiency of active constituents from roots of Panax notoginseng [J]. Phytother Res, 2005, 19 (8): 684–688.
[2] Huang YS, Yang ZC, Yan BG, et al. Improvement of early postburn cardiac function by use of Panax notoginseng and immediate total eschar excision in one operation [J]. Burns, 1999, 25 (1): 35–41.
[3] Zhang W, Wojta J, Binder BR. Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells [J]. Arterioscler Thromb, 1994, 14 (7): 1040–1046.
[4] Wang J, Xu J, Zhong JB, et al. Effect of Radix Notoginseng saponins on platelet activating molecule expression and aggregation in patients with blood hyperviscosity syndrome [J]. CJITWM, 2004, 24 (4): 312–316.
[5] Pan LH, Yuan J, Ding W, et al. Herbal sanqi powder step down plasma coagulation factors I [J]. Chin J New Drugs Clin Rem, 2000, 19 (4): 331–332.
[6] Cun SF, Zhang ZY. Study on effects of 40 cases of coronary heart disease treated with tablet of total saponin of notoginseng [J]. YJTCMMM, 1996, 17 (1): 4–5.
[7] Ren AD, Song YL, Wang GZ, et al. Treatment of coronary heart disease by “XUESETONG”: an observation of 84 cases [J]. PJCM, 1997, 10 (21): 2108–2109.
[8] Bao JC, Liu G, Cong DL, et al. Progress in study on chemical constituens of Panax notoginseng [J]. CTPM, 2006, 18 (2): 246–253.
[9] Wan JB, Yang FQ, Li SP, et al. Chemical characteristics for different parts of Panax notoginseng using pressurized liquid extraction and HPLC-ELSD [J]. J Pharm Biomed Anal, 2006, 41 (5): 1596–1601.
[10] Dong TT, Cui XM, Song ZH, et al. Chemical assessment of roots of Panax notoginseng in China: regional and seasonal variations in its active constituents [J]. J Agric Food Chem, 2003, 51 (16): 4617–4623.
[11] Gao H, Wang F, Lien EJ, et al. Immunostimulating polysaccharides from Panax notoginseng [J]. Pharm Res, 1996, 13 (8): 1196–2000.
[12] Ralevic V, Burnstock G. Receptors for purines and pyrimidines [J]. Pharmacol Rev, 1998, 50 (3): 415–492.
[13] Anfossi G, Russo I, Massucco P, et al. Adenosine increases human platelet levels of cGMP through nitric oxide: possible role in its antiaggregating effect [J]. Thromb Res, 2002, 105 (1): 71–78.
[14] Rozenberg MC, Holmsen H. Adenine nucleotide metabolism of blood platelets. II. Uptake of adenosine and inhibition of ADP-induced platelet aggregation [J]. Biochim Biophys Acta, 1968, 155 (2): 342–352.
[15] Bullough DA, Zhang C, Montag A, et al. Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo [J]. J Clin Invest, 1994, 94 (4): 1524–1532.
[16] Agarwal KC, Clarke E, Rounds S, et al. Platelet-activating factor (PAF)-induced platelet aggregation. Modulation by plasma adenosine and methylxanthines [J]. Biochem Pharmacol, 1994, 48 (10): 1909–1916.
[17] Vuorinen P, Laustiola KE. Exogenous GTP increases cyclic GMP and inhibits thrombin-induced aggregation of washed human platelets: comparison with ATP, adenosine and guanosine [J]. Pharmacol Toxicol, 1992, 71 (4): 289–293.
[18] Okuyama T, Fujita K, Shibata S, et al. Effects of Chinese drugs “xiebai” and “dasuan” on human platelet aggregation (Allium bakeri, A. sativum) [J]. Planta Med, 1989, 55 (3): 242–244.